Return to homepagePandemic Pact

Shutting down emerging Coronaviruses in humans now and in the future [Added supplement: COVID-19 Variant Supplement, Sex as a biological variable supplement]

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 170628, 171488, 175558

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2022

  • Known Financial Commitments (USD)

    $773,688

  • Funder

    Canadian Institutes of Health Research (CIHR)

  • Principal Investigator

    Stephen D Barr

  • Research Location

    Canada

  • Lead Research Institution

    Western University

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

In December 2019, a pneumonia associated with the 2019 novel coronavirus SARS-CoV-2 emerged in Wuhan, China. This disease is now named COVID-19. Over 73,000 people have been infected worldwide and over 1,700 people have died from the disease. There is no sign that the rate of new infections and deaths are levelling off or showing signs of declining. Similar coronavirus outbreaks in the future are always a risk and must be addressed now. The goal of this proposal is to establish and test an effective vaccine for SARS-CoV-2. In addition, we will develop a coronavirus vaccine bank containing hundreds to thousands of potential vaccines that can be used at the start of the next coronavirus outbreak. This will give us a head start in trying to treat patients early with the goal of reducing the spread of the disease and subsequent fatalities.